|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sayed D and Abdellatif M: MicroRNAs in
development and disease. Physiol Rev. 91:827–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang M, Wang J, Kong X, Chen H, Wang Y,
Qin M, Lin Y, Chen H, Xu J, Hong J, et al: miR-198 represses tumor
growth and metastasis in colorectal cancer by targeting fucosyl
transferase 8. Sci Rep. 4:61452014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang J, Zhao H, Xin Y and Fan L:
MicroRNA-198 inhibits proliferation and induces apoptosis of lung
cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marin-Muller C, Li D, Bharadwaj U, Li M,
Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC and Yao Q: A
tumorigenic factor interactome connected through tumor suppressor
microRNA-198 in human pancreatic cancer. Clin Cancer Res.
19:5901–5913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vychytilova-Faltejskova P, Kiss I, Klusova
S, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova
J, Kren L, et al: MiR-21, miR-34a, miR-198 and miR-217 as
diagnostic and prognostic biomarkers for chronic pancreatitis and
pancreatic ductal adenocarcinoma. Diagn Pathol. 10:382015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elfimova N, Sievers E, Eischeid H,
Kwiecinski M, Noetel A, Hunt H, Becker D, Frommolt P, Quasdorff M,
Steffen HM, et al: Control of mitogenic and motogenic pathways by
miR-198, diminishing hepatoma cell growth and migration. Biochim
Biophys Acta. 1833:1190–1198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan S, Li R, Ding K, Lobie PE and Zhu T:
miR-198 inhibits migration and invasion of hepatocellular carcinoma
cells by targeting the HGF/c-MET pathway. FEBS Lett. 585:2229–2234.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qi B, Yao WJ, Zhao BS, Qin XG, Wang Y,
Wang WJ, Wang TY, Liu SG and Li HC: Involvement of microRNA-198
overexpression in the poor prognosis of esophageal cancer. Asian
Pac J Cancer Prev. 14:5073–5076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Awakura Y, Nakamura E, Takahashi T, Kotani
H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T, et
al: Microarray-based identification of CUB-domain containing
protein 1 as a potential prognostic marker in conventional renal
cell carcinoma. J Cancer Res Clin Oncol. 134:1363–1369. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hooper JD, Zijlstra A, Aimes RT, Liang H,
Claassen GF, Tarin D, Testa JE and Quigley JP: Subtractive
immunization using highly metastatic human tumor cells identifies
SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein
antigen. Oncogene. 22:1783–1794. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ikeda J, Oda T, Inoue M, Uekita T, Sakai
R, Okumura M, Aozasa K and Morii E: Expression of CUB domain
containing protein (CDCP1) is correlated with prognosis and
survival of patients with adenocarcinoma of lung. Cancer Sci.
100:429–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Ong SE, Badu-Nkansah K, Schindler
J, White FM and Hynes RO: CUB-domain-containing protein 1 (CDCP1)
activates Src to promote melanoma metastasis. Proc Natl Acad Sci
USA. 108:1379–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyazawa Y, Uekita T, Hiraoka N, Fujii S,
Kosuge T, Kanai Y, Nojima Y and Sakai R: CUB domain-containing
protein 1, a prognostic factor for human pancreatic cancers,
promotes cell migration and extracellular matrix degradation.
Cancer Res. 70:5136–5146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uekita T and Sakai R: Roles of CUB
domain-containing protein 1 signaling in cancer invasion and
metastasis. Cancer Sci. 102:1943–1948. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benes CH, Wu N, Elia AE, Dharia T, Cantley
LC and Soltoff SP: The C2 domain of PKCdelta is a phosphotyrosine
binding domain. Cell. 121:271–280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uekita T, Jia L, Narisawa-Saito M, Yokota
J, Kiyono T and Sakai R: CUB domain-containing protein 1 is a novel
regulator of anoikis resistance in lung adenocarcinoma. Mol Cell
Biol. 27:7649–7660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikeda JI, Morii E, Kimura H, Tomita Y,
Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T
and Aozasa K: Epigenetic regulation of the expression of the novel
stem cell marker CDCP1 in cancer cells. J Pathol. 210:75–84. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seidel J, Kunc K, Possinger K, Jehn C and
Lüftner D: Effect of the tyrosine kinase inhibitor lapatinib on
CUB-domain containing protein (CDCP1)-mediated breast cancer cell
survival and migration. Biochem Biophys Res Commun. 414:226–232.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cermak T, Doyle EL, Christian M, Wang L,
Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ and Voytas
DF: Efficient design and assembly of custom TALEN and other TAL
effector-based constructs for DNA targeting. Nucleic Acids Res.
39:e822011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sundaram GM, Common JE, Gopal FE, Srikanta
S, Lakshman K, Lunny DP, Lim TC, Tanavde V, Lane EB and Sampath P:
‘See-saw’ expression of microRNA-198 and FSTL1 from a single
transcript in wound healing. Nature. 495:103–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uekita T, Tanaka M, Takigahira M, Miyazawa
Y, Nakanishi Y, Kanai Y, Yanagihara K and Sakai R:
CUB-domain-containing protein 1 regulates peritoneal dissemination
of gastric scirrhous carcinoma. Am J Pathol. 172:1729–1739. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Emerling BM, Benes CH, Poulogiannis G,
Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS,
Brown V, et al: Identification of CDCP1 as a hypoxia-inducible
factor 2α (HIF-2α) target gene that is associated with survival in
clear cell renal cell carcinoma patients. Proc Natl Acad Sci USA.
110:3483–3488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kollmorgen G, Niederfellner G, Lifke A,
Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R and
Bossenmaier B: Antibody mediated CDCP1 degradation as mode of
action for cancer targeted therapy. Mol Oncol. 7:1142–1151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
